Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Other financing activities (2018 - 2026)

Dexcom has reported Other financing activities over the past 9 years, most recently at -$1.9 million for Q1 2026.

  • Quarterly Other financing activities fell 11.76% to -$1.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$7.2 million through Mar 2026, down 20.0% year-over-year, with the annual reading at -$7.0 million for FY2025, 46.15% up from the prior year.
  • Other financing activities was -$1.9 million for Q1 2026 at Dexcom, roughly flat from -$1.9 million in the prior quarter.
  • Over five years, Other financing activities peaked at $4.9 million in Q4 2023 and troughed at -$8.7 million in Q1 2024.
  • The 5-year median for Other financing activities is -$1.7 million (2025), against an average of -$2.2 million.
  • Year-over-year, Other financing activities plummeted 975.0% in 2022 and then skyrocketed 590.0% in 2023.
  • A 5-year view of Other financing activities shows it stood at -$1.0 million in 2022, then skyrocketed by 590.0% to $4.9 million in 2023, then tumbled by 132.65% to -$1.6 million in 2024, then decreased by 18.75% to -$1.9 million in 2025, then changed by 0.0% to -$1.9 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Other financing activities are -$1.9 million (Q1 2026), -$1.9 million (Q4 2025), and -$1.7 million (Q3 2025).